{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:50:14Z","timestamp":1778251814875,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jsps.2023.101819","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T16:12:47Z","timestamp":1696522367000},"page":"101819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Herb-drug interaction: Effect of sinapic acid on the pharmacokinetics of dasatinib in rats"],"prefix":"10.1007","volume":"31","author":[{"given":"Mudassar","family":"Shahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajaz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Raish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef A","family":"Bin Jardan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid M.","family":"Alkharfy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Ahad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd","family":"Abul Kalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mushtaq","family":"Ahmad Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffer","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naushad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad I.","family":"Al-Jenoobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.jsps.2023.101819_b0005","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pharep.2018.10.018","article-title":"Dasatinib significantly reduced in vivo exposure to cyclosporine in a rat model: The possible involvement of CYP3A induction","volume":"71","author":"Abdelgalil","year":"2019","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.jsps.2023.101819_b0010","doi-asserted-by":"crossref","first-page":"e4674","DOI":"10.1002\/bmc.4674","article-title":"UPLC-MS\/MS study of the effect of dandelion root extract on the plasma levels of the selected irreversible tyrosine kinase inhibitors dasatinib, imatinib and nilotinib in rats: Potential risk of pharmacokinetic interactions","volume":"33","author":"Alzoman","year":"2019","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jsps.2023.101819_b0015","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428190802136384","article-title":"Dasatinib-induced acute hepatitis","volume":"49","author":"Bonvin","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jsps.2023.101819_b0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tips.2005.11.009","article-title":"Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs","volume":"27","author":"Breedveld","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jsps.2023.101819_b0025","doi-asserted-by":"crossref","first-page":"3571614","DOI":"10.1155\/2016\/3571614","article-title":"Sinapic acid and its derivatives as medicine in oxidative stress-induced diseases and aging","volume":"2016","author":"Chen","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.jsps.2023.101819_b0030","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1124\/jpet.109.154781","article-title":"P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib","volume":"330","author":"Chen","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jsps.2023.101819_b0035","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1124\/dmd.107.018267","article-title":"Metabolism and disposition of dasatinib after oral administration to humans","volume":"36","author":"Christopher","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jsps.2023.101819_b0040","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles","volume":"50","author":"Di Gion","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jsps.2023.101819_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acr.2014.10.001","article-title":"Apical ABC transporters and cancer chemotherapeutic drug disposition","volume":"125","author":"Durmus","year":"2015","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.jsps.2023.101819_b0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00280-004-0832-z","article-title":"Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects","volume":"54","author":"Dutreix","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jsps.2023.101819_b0055","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1177\/0091270009333854","article-title":"Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects","volume":"49","author":"Eley","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jsps.2023.101819_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121851","article-title":"Simultaneous quantitative determination of seven novel tyrosine kinase inhibitors in plasma by a validated UPLC-MS\/MS method and its application to human microsomal metabolic stability study","volume":"1136","author":"Ezzeldin","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jsps.2023.101819_b0065","unstructured":"FDA, 2018. Guidance for industry: bioanalytical method validation. Food Drug Administration U. FDA."},{"key":"10.1016\/j.jsps.2023.101819_b0070","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jps.24289","article-title":"Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction","volume":"104","author":"Fleisher","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jsps.2023.101819_b0075","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.0306-5251.2001.01469.x","article-title":"Herb-drug interactions: review and assessment of report reliability","volume":"52","author":"Fugh-Berman","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jsps.2023.101819_b0080","unstructured":"Gardiner, P., R. S. Phillips and A. F. J. A. f. p. Shaughnessy, 2008. Herbal and dietary supplement-drug interactions in patients with chronic illnesses. American family physician. 77, 73-78."},{"key":"10.1016\/j.jsps.2023.101819_b0085","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jsps.2023.101819_b0090","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jsps.2023.101819_b0095","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ctrv.2015.03.005","article-title":"Variability in bioavailability of small molecular tyrosine kinase inhibitors","volume":"41","author":"Herbrink","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jsps.2023.101819_b0100","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3892\/ol.2016.4780","article-title":"Therapeutic drug monitoring and tyrosine kinase inhibitors","volume":"12","author":"Herviou","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.jsps.2023.101819_b0105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.14712\/23362936.2019.10","article-title":"Pharmacokinetics of dasatinib","volume":"120","author":"Horinkova","year":"2019","journal-title":"Prague Med. Rep."},{"key":"10.1016\/j.jsps.2023.101819_b0110","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1124\/dmd.106.010033","article-title":"Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes","volume":"34","author":"Jigorel","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jsps.2023.101819_b0115","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/cncr.24927","article-title":"Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors","volume":"116","author":"Johnson","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jsps.2023.101819_b0120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","article-title":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL","volume":"61","author":"Kamath","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jsps.2023.101819_b0125","doi-asserted-by":"crossref","unstructured":"Keam, S., 2008. Dasatinib. Bio-Drugs. 22, 59-69.","DOI":"10.2165\/00063030-200822010-00007"},{"key":"10.1016\/j.jsps.2023.101819_b0130","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1021\/jf011348w","article-title":"Antioxidant properties of ferulic acid and its related compounds","volume":"50","author":"Kikuzaki","year":"2002","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.jsps.2023.101819_b0135","doi-asserted-by":"crossref","unstructured":"Meesters, R. and S. J. J. A. B. Voswinkel, 2018. Bioanalytical Method Development and Validation: from the USFDA 2001 to the USFDA 2018 Guidance for Industry. 4, 67-73.","DOI":"10.17145\/jab.18.010"},{"key":"10.1016\/j.jsps.2023.101819_b0140","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ejps.2008.01.008","article-title":"Coordinated induction of drug transporters and phase I and II metabolism in human liver slices","volume":"33","author":"Olinga","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jsps.2023.101819_b0145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7150\/ijms.1.101","article-title":"Tyrosine kinase - Role and significance in cancer","volume":"1","author":"Paul","year":"2004","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.jsps.2023.101819_b0150","doi-asserted-by":"crossref","first-page":"13469","DOI":"10.1016\/S0021-9258(18)92717-1","article-title":"Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms","volume":"266","author":"Porter","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsps.2023.101819_b0155","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eplepsyres.2019.03.012","article-title":"Effects of sinapic acid on hepatic cytochrome P450 3A2, 2C11, and intestinal P-glycoprotein on the pharmacokinetics of oral carbamazepine in rats: Potential food\/herb-drug interaction","volume":"153","author":"Raish","year":"2019","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jsps.2023.101819_b0160","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jfda.2018.06.002","article-title":"Effect of sinapic acid on aripiprazole pharmacokinetics in rats: Possible food drug interaction","volume":"27","author":"Raish","year":"2019","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.jsps.2023.101819_b0165","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.3390\/molecules28041602","article-title":"Effects of apigenin on pharmacokinetics of dasatinib and probable interaction mechanism","volume":"28","author":"Raish","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jsps.2023.101819_b0170","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jms.1369","article-title":"Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry","volume":"43","author":"Rochat","year":"2008","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jsps.2023.101819_b0175","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jsps.2023.101819_b0180","unstructured":"Squibb, B.-M. J. P., NJ, Bristol-Myers Squibb, 2017. Sprycel (dasatinib)."},{"key":"10.1016\/j.jsps.2023.101819_b0185","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jsps.2023.101819_b0190","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bcp.12496","article-title":"Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations","volume":"79","author":"Teo","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jsps.2023.101819_b0195","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1055\/s-0032-1327702","article-title":"Simultaneous determination of methotrexate, dasatinib and its active metabolite N-deshydroxyethyl dasatinib in rat plasma by LC-MS\/MS: method validation and application to pharmacokinetic study","volume":"62","author":"Thappali","year":"2012","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.jsps.2023.101819_b0200","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1073\/pnas.76.9.4350","article-title":"Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications","volume":"76","author":"Towbin","year":"1979","journal-title":"PNAS"},{"key":"10.1016\/j.jsps.2023.101819_b0205","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"van Erp","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jsps.2023.101819_b0210","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jsps.2023.101819_b0215","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1124\/dmd.107.020255","article-title":"Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics","volume":"36","author":"Wang","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jsps.2023.101819_b0220","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lfs.2007.05.007","article-title":"Anxiolytic-like effects of sinapic acid in mice","volume":"81","author":"Yoon","year":"2007","journal-title":"Life Sci."},{"key":"10.1016\/j.jsps.2023.101819_b0225","unstructured":"Zou, Y.-N., A.-R. Kim, J.-E. Kim, et al., 2002. Peroxynitrite Scavenging Activity of Sinapic Acid. Proceedings of the PSK Conference, The Pharmaceutical Society of Korea."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016423003146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016423003146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:29:03Z","timestamp":1736184543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016423003146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1319016423003146"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2023.101819","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Herb-drug interaction: Effect of sinapic acid on the pharmacokinetics of dasatinib in rats","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2023.101819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}],"article-number":"101819"}}